With the Festival of Genomics London just around the corner, we thought it was the right time to turn our attention to the key themes being presented.
As the volume and depth of genomic data grows, bioinformaticians are translating genomic data into interpretable patterns leading to new biological insight.
A group of well-known companies aims to be the first to analyse brain scans together with genomic, clinical and phenotypic data to study neurodegenerative diseases at a population level, then distil it down to an individual’s personal treatment plan.
Microscopes enhanced with AI could help clinical microbiologists diagnose potentially deadly blood infections and improve patients’ odds of survival.
Colin’s lab processes about 350,000 samples a year in order to generate ~800,000 genotypes on very complex genetic models, we’ve talked to him ahead of the Festival.
As former leader and founder Nessan Bermingham walks away from Intellia Therapuetics, it has named John Leonard as its new president and chief.
Several individual investors from Illumina have invested in an open-source genomics database that uses the same technology employed by Bitcoin.
The Human Rights Watch has questionned the motives behind Chinese authorities collecting DNA samples from the Xinjiang region.
There are a number of challenges that exist when biotech companies prepare to take a promising compound to a commercially viable product.
Researchers at the Commonwealth Scientific and Research Organisation have developed a cloud-based tool, to help tackle big data challenges.
Chinese chemical manufacturing firm Boai NKY Pharmaceuticals plans to purchase BioVision Inc., a drug screening specialist headquartered in San Francisco.
As the year draws to a close, Rick Duprey, writing for The Motley Fool, takes a look back at three biotechs that have quadrupled this year.
With 2017 coming to a close, the biopharma industry and the US Food and Drug Administration (FDA) are preparing to face a very busy time.